Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MacroGenics’ Investigational Product Candidates
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
MacroGenics and its collaboration partners are conducting clinical studies that explore the use of product candidates developed by MacroGenics in different cancer settings. The product candidates listed below are investigational, in that they are being evaluated in clinical trials and are not yet approved for use by regulatory authorities. Approval by regulatory authorities around the world, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is required to make our medicine available to the patients. Therefore, our priority is to enroll patients in clinical trials in order to obtain the data required for review and approval by regulatory authorities.
MacroGenics studies that are currently recruiting patients for our investigational product candidates include:
Hematological Malignancies
CD123-positive malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
Solid Tumors
Prostate Cancer
Advanced Solid Tumors